Drug · CHEMBL1111
AMBRISENTAN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. AMBRISENTAN. Drugs and targets, record CHEMBL1111. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1111
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 3 of its 20 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| EDNRA | Endothelin receptor, ET-A/ET-B | Endothelin receptor, ET-A/ET-B antagonist | ANTAGONIST | https://conductscience.org/library/genes/1909 |
| EDNRB | Endothelin receptor, ET-A/ET-B | Endothelin receptor, ET-A/ET-B antagonist | ANTAGONIST | https://conductscience.org/library/genes/1910 |
Source ChEMBL
Diseases20
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| pulmonary arterial hypertension | Approval | DailyMed, PMDA and TTD | 33 | 29 | https://conductscience.org/library/drugs?q=MONDO_0015924 |
| pulmonary hypertension | Approval | EMA Human Drugs | 8 | 5 | https://conductscience.org/library/drugs?q=MONDO_0005149 |
| COVID-19 | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0100096 |
| Pulmonary arterial hypertension associated with portal hypertension | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=EFO_0009197 |
| chronic thromboembolic pulmonary hypertension | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=EFO_0022954 |
| idiopathic pulmonary fibrosis | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=EFO_0000768 |
| systemic sclerosis | Unknown | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005100 |
| Moderate albuminuria | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0012594 |
| Pain | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0012531 |
| Proteinuria | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0000093 |
1 to 10 of 20Source Open Targets
See all 20 diseasesTrials63
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01178073 | A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) | Phase 3 | 610 | 2015-04-28 | ambrisentan | Its name | ClinicalTrials.gov |
| NCT00768300 | (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF | Phase 3 | 494 | 2014-04-08 | ambrisentan | Its name | ClinicalTrials.gov |
| NCT00578786 | A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) | Phase 3 | 383 | 2013-01-15 | ambrisentan | Its name | ClinicalTrials.gov |
| NCT00380068 | Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension | Phase 3 | 224 | 2010-11-19 | ambrisentan | Its name | ClinicalTrials.gov |
| NCT00777920 | Study of Ambrisentan in Participants With Pulmonary Hypertension | Phase 3 | 140 | 2020-09-30 | ambrisentan | Its name | ClinicalTrials.gov |
| NCT01808313 | Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH) | Phase 3 | 134 | 2015-05-12 | ambrisentan | Its name | ClinicalTrials.gov |
| NCT02688387 | A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects | Phase 1 | 112 | 2019-01-22 | ambrisentan | Its name | ClinicalTrials.gov |
| NCT00424021 | Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension | Phase 2 | 54 | 2012-01-27 | ambrisentan | Its name | ClinicalTrials.gov |
| NCT01332331 | Efficacy and Safety of Ambrisentan in Children 8-18yrs | Phase 2 | 41 | 2019-10-08 | ambrisentan | Its name | ClinicalTrials.gov |
| NCT00879229 | ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis | Phase 3 | 40 | 2014-04-22 | ambrisentan | Its name | ClinicalTrials.gov |
1 to 10 of 63
See all 63 trialsComparisons in its trials24
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ambrisentan vs Placebo: serious adverse events | 73 of 329 | 25 of 163 | 492 | NCT00768300 | Trial comparisons |
| Low Dose Ambrisentan vs High Dose Ambrisentan: deaths from any cause | 1 of 21 | 0 of 20 | 41 | NCT01332331 | Trial comparisons |
| Low Dose Ambrisentan vs High Dose Ambrisentan: serious adverse events | 6 of 21 | 2 of 20 | 41 | NCT01332331 | Trial comparisons |
| Ambrisentan vs Placebo: serious adverse events | 12 of 25 | 3 of 15 | 40 | NCT00879229 | Trial comparisons |
| On Ambrisentan Therapy vs On Placebo: deaths from any cause | 0 of 19 | 0 of 19 | 38 | NCT01971580 | Trial comparisons |
| On Ambrisentan Therapy vs On Placebo: serious adverse events | 1 of 19 | 0 of 19 | 38 | NCT01971580 | Trial comparisons |
| Ambrisentan Verum vs Placebo: deaths from any cause | 0 of 19 | 0 of 19 | 38 | NCT02290613 | Trial comparisons |
| Ambrisentan Verum vs Placebo: serious adverse events | 1 of 19 | 5 of 19 | 38 | NCT02290613 | Trial comparisons |
| Ambrisentan 5mg vs Placebo: Number of Participants With Significant Liver Events at Weeks 4, 8, 12, and 16/Early Withdrawal | 0 of 17 | 0 of 16 | 33 | NCT01884675 | Trial comparisons |
| Ambrisentan 5mg vs Placebo: Number of Participants With Clinical Worsening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) | 0 of 17 | 0 of 16 | 33 | NCT01884675 | Trial comparisons |
1 to 10 of 24
See all 24 comparisons in its trialsPapers from its trials33
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 23648946 | RESULT | 1 | PubMed |
| 22777623 | RESULT | 1 | PubMed |
| 41653169 | DERIVED | 1 | PubMed |
| 37378404 | DERIVED | 1 | PubMed |
| 37332660 | DERIVED | 1 | PubMed |
| 37254256 | DERIVED | 1 | PubMed |
| 36579617 | DERIVED | 1 | PubMed |
| 34473343 | DERIVED | 1 | PubMed |
| 32799568 | DERIVED | 1 | PubMed |
| 32736592 | DERIVED | 1 | PubMed |
1 to 10 of 33
See all 33 papers from its trialsTests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1111
GET https://conductscience.org/api/drugs/v1/CHEMBL1111/trials?page=2